Apply to trial NCT06684522

A few quick questions so the study team can decide if you might be a fit.

RecruitingEarly Phase 1Drug trial

Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis

This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening